Interview with Germano Carganico, General Manager, Toscana Life Sciences
Italians are often praised to make up deficiencies of the country at national level with more creativity at a regional level- which is why Science Parks are coordinated at the…
Recipharm was established in Sweden in 1995 and has since then grown to become a leading Contract Development and Manufacturing Organisation (CDMO) and is headquartered close to Stockholm.
Today, Recipharm operates 25 facilities in 10 countries (France, Germany, India, Italy, Israel, Portugal, Spain, Sweden, USA and the UK) covering most of the pharmaceutical dosage forms. Recipharm employs around 4.000 people and is listed on NASDAQ Stockholm.
In October 2014 Recipharm acquired Italian Corvette Group including all the operating companies based in Milan (Biologici Italia Laboratories, Edmond Pharma, Liosintex).
In February 2016 Mitim, located in Brescia, was acquired.
In Italy Recipharm operates four manufacturing facilities, specialized in parenterals of freeze-dried and liquid vials and ampoules, lyophilisation of sterile beta-lactam antibiotics in bulk, filling of beta-lactams powder, APIs synthesis oral solid form, Erdosteine business (API synthesis and finished dosages).
Recipharm has the competence, flexibility and facilities to take on challenging projects which require custom tailored processes. With a broad range of expertise and technologies available, Recipharm offers support and services ranging from development and procurement to full-scale manufacturing, distribution, technology transfer and stability studies. In addition to human pharmaceuticals, Recipharm can also supply medical devices and veterinary products.
Please visit our web site: www.recipharm.com
Italians are often praised to make up deficiencies of the country at national level with more creativity at a regional level- which is why Science Parks are coordinated at the…
Italfarmaco counts amongst the few players who really sustained the growth of the Italian pharmaceutical industry in the past 10 years. Which specific values would you quote as keys to…
You created Abiogen in 1997, following the acquisition of Istituto Gentili by MSD, in order to maintain your family’s entrepreneurial tradition, keeping building on the legacy of your great-grandfather Commendatore…
Recordati was created in 1926, and the combined work of three generations turned the small laboratory not only into a local success story but also a broad European Group. Your…
Following the successful result of the “Piano Sanitario Nazionale” 2005 – 2008, could you introduce to ours readers the key priorities and main health policies to be implemented by 2009…
Following 20 years of a comprehensive experience in diverse fields of the pharmaceutical industry, you entered Baxter in 2000. At the time, the Italian affiliate was already a well established…
Despite Italy being one of the most important pharmaceutical markets not only in Europe but also in the World, the industry remained quite stable for the last two years and…
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
Having led a 26 years long career in Pfizer, you have been involved in a number of different countries including leading markets such as the US and Japan, but also…
You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical…
Since 1982, CNR has been the Italian public body which most contributed to the creation of inventions and innovations. What have been the main strategies behind such a success in…
Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and…
See our Cookie Privacy Policy Here
